Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2025-03-19 00:00:00 ET · period of report 2025-03-17 · accession 0001601830-25-000047 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-19 | 2025-03-17 | RXRX | Sun Elaine D | Dir | A - Grant | $0.00 | +36.5K | 36.5K | New | $0 |
| D | 2025-03-19 | 2025-03-17 | RXRX | Sun Elaine D | Dir | A - Grant | $0.00 | +73.1K | 73.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-03-17 | A | A | 36,549 | $0.00 | 36,549 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-03-17 | A | A | 73,099 | $0.00 | 73,099 | D | $6.84 · — to 2035-03-17 | 73,099 Class A Common Stock | (F2) Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. |